Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.
G. Von Minckwitz
No relevant relationships to disclose
M. Kaufmann
No relevant relationships to disclose
S. Kuemmel
No relevant relationships to disclose
P. A. Fasching
Consultant or Advisory Role - Novartis
Honoraria - AstraZeneca; Novartis; Pfizer
W. Eiermann
No relevant relationships to disclose
J. U. Blohmer
No relevant relationships to disclose
S. D. Costa
No relevant relationships to disclose
J. Hilfrich
No relevant relationships to disclose
C. Jackisch
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; Roche
B. Gerber
Honoraria - AstraZeneca; GlaxoSmithKline; Novartis; Roche; Sanofi
Research Funding - Novartis
A. Du Bois
Consultant or Advisory Role - AstraZeneca; Roche
Honoraria - AstraZeneca; Roche
Research Funding - AstraZeneca; Roche
J. B. Huober
Consultant or Advisory Role - GlaxoSmithKline; Roche; Sanofi
Honoraria - Sanofi
Research Funding - GlaxoSmithKline
C. A. Hanusch
No relevant relationships to disclose
G. E. Konecny
Research Funding - Amgen; GlaxoSmithKline
W. Fett
No relevant relationships to disclose
E. Stickeler
No relevant relationships to disclose
N. Harbeck
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche
K. Mehta
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose